The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...
RedRidge will hold exclusive commercial rights in the United States, Canada, and Japan for both programs, while Pierre Fabre Laboratories will hold exclusive rest-of-world rights. In addition ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback